Antipsychotic

This page covers all Antipsychotic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine D2 receptor; Serotonin 5-HT2A receptor, Dopamine D2 receptor, Serotonin 5-HT2A receptor, Dopamine D2 receptors.

Targets

Dopamine D2 receptor; Serotonin 5-HT2A receptor · Dopamine D2 receptor, Serotonin 5-HT2A receptor · Dopamine D2 receptors

Marketed (3)

• Standard of Care Oral antipsychotics · University of Utah · Psychiatry
  Standard of care oral antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
• Risperidone, Haloperidol · Ludwig-Maximilians - University of Munich · Psychiatry/Neurology
  Risperidone and haloperidol are antipsychotic medications that block dopamine and serotonin receptors in the brain to reduce psychotic symptoms.
• Flupentixole · Technical University of Munich · Neuroscience
  Flupentixole is a dopamine D2 receptor antagonist that reduces psychotic symptoms by blocking dopamine receptors in the brain.

Phase 3 pipeline (1)

• Antipsychotic treatment · Fundación Pública Andaluza Progreso y Salud · Psychiatry/Neurology
  Antipsychotic treatment works by modulating dopamine and/or serotonin neurotransmission in the brain to reduce psychotic symptoms.